Repare Therapeutics Inc. (RPTX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Repare Therapeutics Inc.
Address
7210 Frederick-Banting
Montreal, QC H4S 2A1
Canada
Phone
857 412 7018
Website
Sector
Healthcare
Industry
Biotechnology
Employees
129
First IPO Date
June 19, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Steve Forte | President, Chief Financial Officer, Chief Executive Officer & Director | 631,996 | 1979 |
| Michael Zinda | Executive Vice President & Chief Scientific Officer | 661,153 | 1971 |
| Daniel Durocher | Co-Founder | 0 | N/A |
| Sandra Alves | Senior Vice President & Chief Accounting Officer | 0 | 1979 |
| Agnel Sfeir | Co-Founder | 0 | N/A |
| Frank Sicheri | Co-Founder | 0 | N/A |
| Joseph O'Connell | Executive Vice President of Clinical Development and Medical Affairs | 0 | 1954 |
| Daniel Belanger | Executive Vice President of Human Resources | 0 | N/A |
Description
Repare Therapeutics Inc. is a precision oncology biopharmaceutical company in the clinical stage, focused on discovering and developing innovative therapies. Operating across Canada and the United States, the company leverages a synthetic lethality approach to identify new treatments. Central to their efforts is the proprietary, genome-wide, and CRISPR-enabled SNIPRx platform, which systematically uncovers and advances highly targeted cancer medicines. These therapies are specifically designed to address genomic instability, particularly related to DNA damage repair mechanisms. Their primary investigational drug is RP-3500, an oral small molecule inhibitor currently being developed to treat solid tumors that possess specific genomic alterations linked to DNA damage repair. Repare is also advancing RP-6306, which is in Phase I clinical trials for tumors characterized by genetic alterations involving CCNE1 amplification. Furthermore, the company is pursuing a Polymerase Theta program, investigating a synthetic lethal target relevant to BRCA mutations and other genomic abnormalities. Repare Therapeutics Inc. was established in 2016 and maintains its headquarters in Montreal, Canada.
